Zejula (niraparib)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Zejula (niraparib)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Zejula (niraparib) may be approved if the following criteria are met:

I. Individual has deleterious or suspected deleterius germline BRCA-mutated recurrent, ovarian cancer, including epithelial, fallopian tube, or primary peritoneal (Label, NCCN 1); **AND**
II. Individual is using for maintenance treatment; **AND**
III. Individual had a complete or partial response to a platinum-based chemotherapy;

OR

IV. Individual has advanced epithelial ovarian, fallopian, or primary peritoneal cancer (Label); **AND**
    A. Individual is using for maintenance treatment; **AND**
    B. Individual has a complete or partial response to first-line platinum-based chemotherapy;

OR

V. Individual has a diagnosis of advanced, recurrent, or metastatic uterine neoplasms (NCCN 2A);
    A. Individual is using as a single agent; **AND**
    B. Individual has germline or somatic BRCA mutation; **AND**
    C. Individual is using as second-line or subsequent therapy.

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2023. URL: http://www.clinicalpharmacology.com. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed: June 28, 2023
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2023; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2023 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: http://www.nccn.org/index.asp. Accessed on June 28, 2023.
    a. Ovarian Cancer. V2.2023. Revised June 2, 2023
    b. Uterine Neoplasms. V2.2023. Revised April 28, 2023.